AstraZeneca $AZN inked a deal with Allergan $AGN valued at $1.52bn in which the latter will buy rights to an antibody for Crohn�s disease. As per the terms of the deal, Allergan will pay $250mn upfront; however, it might have to pay up to $1.278bn over the course of 15 years, tied to potential sales of the antibody, branded as MEDI2070�an anti-IL-23 monoclonal antibody, which is at present under Phase 2b clinical development. The deal includes launch milestone payments up to $435mn and sales-based milestones of $725mn in addition to royalties.